Literature DB >> 7759077

Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect.

H Brauch1, T Kishida, D Glavac, F Chen, F Pausch, H Höfler, F Latif, M I Lerman, B Zbar, H P Neumann.   

Abstract

We identified a germline missense mutation at nucleotide 505 (T to C) of the VHL tumor suppressor gene in 14, apparently unrelated, VHL type 2A families from the Black Forest region of Germany. This mutation was previously identified in two VHL 2A families living in Pennsylvania (USA). All affected individuals in the 16 families shared the same VHL haplotype indicating a founder effect. This missense mutation at codon 169 (Tyr to His) would probably cause an alteration in the structure of the putative VHL protein. The association of this distinct mutation with the pheochromocytoma phenotype in VHL may help to elucidate the genetic mechanism of carcinogenesis in this multi tumor cancer syndrome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759077     DOI: 10.1007/BF00223868

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  21 in total

Review 1.  Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome.

Authors:  H P Neumann
Journal:  Vasa       Date:  1987       Impact factor: 1.961

2.  Diagnosis of genetic disease by primer-specified restriction map modification, with application to cystic fibrosis and retinitis pigmentosa.

Authors:  E J Sorscher; Z Huang
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

3.  Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus.

Authors:  G M Glenn; L N Daniel; P Choyke; W M Linehan; E Oldfield; M B Gorin; S Hosoe; F Latif; G Weiss; M Walther
Journal:  Hum Genet       Date:  1991-06       Impact factor: 4.132

4.  Specific genetic change in tumors associated with von Hippel-Lindau disease.

Authors:  K Tory; H Brauch; M Linehan; D Barba; E Oldfield; M Filling-Katz; B Seizinger; Y Nakamura; R White; F F Marshall
Journal:  J Natl Cancer Inst       Date:  1989-07-19       Impact factor: 13.506

5.  Clinical features and natural history of von Hippel-Lindau disease.

Authors:  E R Maher; J R Yates; R Harries; C Benjamin; R Harris; A T Moore; M A Ferguson-Smith
Journal:  Q J Med       Date:  1990-11

6.  Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease.

Authors:  H P Neumann; D P Berger; G Sigmund; U Blum; D Schmidt; R J Parmer; B Volk; G Kirste
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

7.  Renal pathology in von Hippel-Lindau disease.

Authors:  D Solomon; A Schwartz
Journal:  Hum Pathol       Date:  1988-09       Impact factor: 3.466

8.  Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype.

Authors:  F Chen; T Kishida; M Yao; T Hustad; D Glavac; M Dean; J R Gnarra; M L Orcutt; F M Duh; G Glenn
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

9.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

10.  Isolation and characterization of 19 dinucleotide repeat polymorphisms on chromosome 3p.

Authors:  M H Jones; K Yamakawa; Y Nakamura
Journal:  Hum Mol Genet       Date:  1992-05       Impact factor: 6.150

View more
  37 in total

1.  Clinical utility gene card for: von Hippel-Lindau (VHL).

Authors:  Jochen Decker; Christine Neuhaus; Fiona Macdonald; Hiltrud Brauch; Eamonn R Maher
Journal:  Eur J Hum Genet       Date:  2013-08-28       Impact factor: 4.246

Review 2.  The von Hippel-Lindau gene: turning discovery into therapy.

Authors:  Peter E Clark; Michael S Cookson
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 3.  The molecular basis of von Hippel-Lindau disease.

Authors:  O Iliopoulos; W G Kaelin
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

4.  Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only.

Authors:  F J Hes; S McKee; M J Taphoorn; P Rehal; R B van Der Luijt; R McMahon; J J van Der Smagt; D Dow; R A Zewald; J Whittaker; C J Lips; F MacDonald; P L Pearson; E R Maher
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

5.  Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.

Authors:  E R Woodward; S C Clifford; D Astuti; N A Affara; E R Maher
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

6.  A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.

Authors:  S Cingoz; R B van der Luijt; E Kurt; M Apaydin; I Akkol; Mihriban Heval Ozgen
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

7.  Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark.

Authors:  Marie Louise Mølgaard Binderup; Michael Galanakis; Esben Budtz-Jørgensen; Michael Kosteljanetz; Marie Luise Bisgaard
Journal:  Eur J Hum Genet       Date:  2016-12-14       Impact factor: 4.246

8.  Detection of germline mutations in the von Hippel-Lindau disease gene by the primer specified restriction map modification method.

Authors:  T Kishida; F Chen; M I Lerman; B Zbar
Journal:  J Med Genet       Date:  1995-12       Impact factor: 6.318

9.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

10.  Mitochondrial and nuclear genes of mitochondrial components in cancer.

Authors:  E Kirches
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.